Next-Generation Bispecific Nanobody Targeting FAP and TNF for Innovative Cancer Therapy

VHH-P519 is an engineered, humanized single-domain nanobody designed to simultaneously target fibroblast activation protein alpha (FAP) and tumor necrosis factor (TNF). Currently in the biological testing phase, this program leverages the unique biology of both FAP and TNF for potential application in the treatment of cancer. By integrating a bispecific antibody framework fused with a TNF-alpha variant and a single-domain FAP-targeting moiety, VHH-P519 embodies a highly innovative modality with the promise of precise tumor targeting and modulation of the tumor microenvironment. This approach aims to enhance the specificity and anti-cancer efficacy of immunotherapeutics addressing significant unmet needs in oncology.

Licensing Opportunity

VHH-P519 is available for out-licensing and collaborative partnership opportunities. We actively welcome inquiries from pharmaceutical and biotechnology partners seeking to access innovative nanobody-based immunotherapeutic solutions in oncology.

Development Phase

Modality

VHH-P519 utilizes a sophisticated immunoconjugate design, featuring a bispecific IgG1 backbone that incorporates a single-domain nanobody specific for FAP via a flexible G(4)S linker. This modality leverages the compact size and unique structural attributes of nanobodies, such as enhanced tissue penetration and stability, which are particularly advantageous for solid tumor targeting in cancer therapy. The conjugate harbors a TNF-alpha variant (S95A) as a functional payload and includes a masking moiety for TNF-alpha, enabling spatial precision and reducing off-target effects. The modularity of the nanobody allows for adaptive engineering, enabling the realization of multi-functional, tailored anti-cancer therapeutics with superior tumor infiltration.

Target

FAP and TNF are pivotal molecular targets in cancer biology, offering distinct and synergistic therapeutic opportunities. FAP, a cell surface serine protease, is predominantly expressed on activated fibroblasts within the tumor stroma and is minimally present in normal tissues, making it an attractive tumor-associated antigen. TNF, a cytokine, regulates inflammation and cellular apoptosis and plays a dual role in cancer progression and immune modulation. The overexpression of FAP in the tumor microenvironment and the involvement of TNF in tumor-induced inflammation underscore the rationale for dual targeting. VHH-P519 strategically addresses both FAP and TNF, maximizing tumor selectivity and immune modulation. This dual-targeting tactic enhances clinical development prospects, situating VHH-P519 as a strategic asset in the oncology pipeline.

Mechanism of Action

VHH-P519 exerts its therapeutic effect through dual inhibition and modulation of both FAP and TNF. By anchoring specifically to FAP-expressing stromal cells in the tumor microenvironment, the nanobody facilitates localized delivery of the TNF-alpha variant, while a masking moiety ensures TNF-alpha activity is spatially restricted and only unmasked within the tumor milieu. This targeted approach enhances anti-tumor immune responses, disrupts tumor-supportive stroma, and limits systemic toxicity. The small and versatile architecture of the single-domain nanobody supports further engineering, enabling the future development of advanced multi-specific formats, including antibody-drug conjugates (ADC) and bispecific immunotherapies, thereby broadening both current and future clinical applications.

Cancer

Cancer remains a principal public health challenge worldwide, impacting a diverse population across all age groups and geographies. Characterized by uncontrolled cellular proliferation and the ability to invade and metastasize, cancer encompasses a multitude of subtypes with unique biological and clinical attributes. Standard treatment modalities include surgery, radiation, chemotherapy, immunotherapy, and emerging targeted therapies. Despite these advances, existing strategies are frequently limited by tumor heterogeneity, therapy resistance, and off-target toxicity. There is a substantial unmet medical need for highly selective, effective interventions that overcome the immunosuppressive tumor microenvironment and enhance patient outcomes. By targeting both the stromal and cytokine components crucial for tumor survival, VHH-P519 offers a novel mechanism with potential to address these limitations and significantly advance cancer therapy.